Drug Trial Radar · NCT05606913
A Study of IBI362 in Participants With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
731
Actual
Start
Jan 6, 2023
Primary completion
Jan 26, 2024
Study completion Apr 9, 2024
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in China. The aim of the trial is to evaluate efficacy and Safety of IBI362 Versus dulaglutide as add-on to Metformin and/or SGLT2 inhibitor or TZD in Subjects With Type 2 Diabetes.
Conditions
- Type 2 Diabetes
Interventions
dulaglutideDrug
Dulaglutide administered subcutaneously (SC) once a week.
IBI362Drug
IBI362 administered subcutaneously (SC) once a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1c change from baseline at week 28Time frame: Baseline, 28 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.